Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200-Day Moving Average – Here’s Why

Tenax Therapeutics, Inc. (NASDAQ:TENX)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.66 and traded as high as $5.09. Tenax Therapeutics shares last traded at $4.93, with a volume of 57,291 shares traded.

Analyst Ratings Changes

TENX has been the topic of a number of research reports. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. StockNews.com started coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. William Blair began coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating for the company. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Tenax Therapeutics Price Performance

The company’s 50-day simple moving average is $3.91 and its 200-day simple moving average is $3.66.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. Equities research analysts forecast that Tenax Therapeutics, Inc. will post -6.62 EPS for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.